Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Phase 1 Terminated
17 enrolled
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
Phase 1 Terminated
272 enrolled
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma
Phase 1 Terminated
12 enrolled
Safety Study of SEA-CD40 in Cancer Patients
Phase 1 Terminated
159 enrolled
A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer
Phase 1 Completed
19 enrolled
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
Phase 1 Terminated
5 enrolled
INPAKT
Phase 1 Completed
52 enrolled
Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
Phase 1 Completed
145 enrolled
Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
Phase 1 Completed
78 enrolled
A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
Phase 1 Terminated
44 enrolled
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
30 enrolled
AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Unknown
18 enrolled
Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
Phase 1 Completed
108 enrolled